TY - JOUR T1 - A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01159-2018 VL - 52 IS - 3 SP - 1801159 AU - Ritesh Agarwal AU - Sahajal Dhooria AU - Inderpaul S. Sehgal AU - Ashutosh N. Aggarwal AU - Mandeep Garg AU - Biman Saikia AU - Arunaloke Chakrabarti Y1 - 2018/09/01 UR - http://erj.ersjournals.com/content/52/3/1801159.abstract N2 - Glucocorticoids are the most widely used agents in the treatment of allergic bronchopulmonary aspergillosis (ABPA), a disorder characterised by immunologic reactions mounted against Aspergillus fumigatus colonising the airways of patients with asthma and cystic fibrosis [1, 2]. Unfortunately, the use of glucocorticoids is associated with several adverse reactions [3]. A novel treatment strategy in ABPA would be the use of antifungal triazoles as monotherapy. Recently, we have shown that itraconazole was effective as monotherapy in acute-stage ABPA [4]. Whether voriconazole monotherapy is also efficacious in acute-stage ABPA remains unknown.Voriconazole monotherapy is as effective, and safer, than glucocorticoids for the treatment of ABPA http://ow.ly/jCix30l2Lb9 ER -